Why the study?
What are the clinical pharmacokinetics of heparin and how do they affect therapeutic dosing?
Population
Patients receiving heparin, including those with pulmonary emboli or deep venous thrombosis
Design
Review
Authors
Loading...
Supports individualized heparin monitoring in PE versus DVT; extends pharmacokinetic observations but leaves open outcome benefits without prospective trials.
What are the clinical pharmacokinetics of heparin and how do they affect therapeutic dosing?
The review highlights the variability in heparin pharmacokinetics, particularly between PE and DVT patients, emphasizing the need for continuous monitoring of clotting times to guide dosing.
Ralph H. Raasch (1980) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: